Novo Nordisk announced a strategic partnership with OpenAI today. AI across drug discovery, manufacturing, commercial operations. Full integration by end of 2026.
Sound familiar? It should.
Sanofi signed with OpenAI in May 2024 (with Formation Bio). Then Moderna. Then Thermo Fisher. Then Eli Lilly. Novo is the latest major pharma to call Sam Altman’s office, and it won’t be the last.
The deal has no disclosed financial terms, no named programs, no specific molecules. CEO Mike Doustdar called it about “supercharging” scientists. The press release reads like every other big pharma AI announcement of the past two years.
But here’s what makes 2026 different from 2024: the capital behind AI drug discovery has gone from speculative to structural. A new landscape report from The Biotech Voyager and FLYTE Intelligence identifies 221 early-stage companies building AI/ML platforms to discover and design therapeutics.
The aggregate deal value across partnerships announced in the past five months alone exceeds $5 billion in total potential milestones.
AI Drug Discovery: Major Signals (Dec 2025 – Apr 2026)
Dec 2025
Insilico Medicine IPO on HKEX ($292M)
Jan 2026
VantAI raises $80M seed round
Feb 2026
Generate Biomedicines IPO on Nasdaq ($400M)
Feb 2026
Iambic Therapeutics + Takeda deal ($1.7B+ potential)
Mar 2026
Insilico + Eli Lilly ($115M upfront, $2.75B total)
Apr 2026
Anthropic acquires Coefficient Bio ($400M, 9 employees)
Apr 2026
Novo Nordisk + OpenAI (terms undisclosed)
Source: FLYTE Intelligence / HOUSTON. Green = funding/IPO. Blue = partnership/M&A.
Let’s take a look at where the money is going.
Insilico Medicine went public in Hong Kong, then signed a deal with Eli Lilly worth up to $2.75B with $115M upfront, the largest upfront payment for an AI drug discovery platform to date.
Iambic Therapeutics locked in a multi-year deal with Takeda exceeding $1.7B in total potential value. Isomorphic Labs, the DeepMind spinout, raised $600M externally.
VantAI raised $80M in a seed round.
And then there’s Anthropic, which skipped the partnership playbook entirely and bought Coefficient Bio outright for ~$400M. Nine employees. Eight months old. That acquisition says more about where this is heading than any enterprise deal.
Novo’s move makes sense in context.
Lilly has signed 16 AI-based deals since 2025, including a $1B Nvidia partnership and the Insilico mega-deal. Novo had its Nvidia/Gefion supercomputer collaboration from last year, but it was falling behind in the optics war.
This OpenAI deal closes that gap on paper.
Whether it closes the gap in the lab is a different question. No AI-discovered drug has received regulatory approval yet. But the companies purpose-built for this, not the ones adding AI to existing workflows, are the ones generating the clinical data that will answer it.
The full AI Drug Discovery Landscape Report, covering all 221 companies, is available for FREE on The Biotech Voyager.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
